Biointron Insights: Antibody Industry Report (Q1 2025 Insights, Trends & Analysis)

Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March). This quarter, 6 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: three from China, two from the EU, and one from Australia:

1. Vilobelimab (Gohibic)

2. Garadacimab (Andembry)

3. Finotonlimab (新替妥)

4. Siltartoxatug (Sintetol)

5. Sipavibart (Kavigale)

6. Teprotumumab N01 (Sycume)

Q1 2025 saw several large collaborations and acquisitions of up to USD$3.1 billion in value. The majority of collaborative efforts focused on developing novel platforms such as bispecific antibody and ADC engineering.

Gain exclusive insights into current trends such as:

• 6 novel antibody drugs approved for the first time in Q1

• Top 10 antibody drug deals, including collaborations, M&As, and funding rounds of up to US$3.1B

• Novel platforms such as bispecific antibody and ADC engineering

• Recent research into obesity and COVID-19 treatments

• A list of antibody drugs in regulatory review to keep an eye out for in Q2 2025